DNA

Latest Headlines

Researchers at the University of Maryland at Baltimore succeeded in delivering nanoparticles into cancer cells that changed packaged DNA into circular DNA, a breakthrough that may have applications for oncology and gene-based therapy.

Drug delivery specialist Genisphere announced that it has raised $2 million in private funding to advance its 3DNA nanotechnology platform through collaborations with pharma companies. The funders are existing investors including Corporate Fuel Partners.

While test strips and expensive polymerase chain reaction (PCR) machines exist in the Ebola detection market, scientists are after a medical device that can detect and prevent the spread of Ebola at a low cost.

Johns Hopkins researchers published a study showing they can use biodegradable nanoparticles to carry DNA to brain cancer cells. The animal study suggests that these vehicles could deliver what they call "death genes" to the cells, treating the cancer while preserving healthy brain cells in the process.

In the 13 years since the publication of the rough draft of the human genetic code, scientists have run thousands of genome-wide association studies to find links between DNA and disease. The work has delivered some insights, but also shown the method has limitations. Now, a new approach could avoid these flaws.

Exact Sciences stock plunged more than 20% late Thursday morning based on what was ostensibly positive early news about a massive pivotal study for the company's colorectal cancer molecular diagnostic test. While the data met all endpoints, investors clearly wanted better and they punished the company as a result.

Work is under way on a diagnostic test that would determine the response of a patient with advanced breast cancer to drug treatment, by measuring the DNA that breaks off from dying tumor cells into the bloodstream.

THE LIBRARY: WEBINAR

In December 2014, FDA released the Guidance for Industry "Providing Regulatory Submissions in Electronic Format—Standardized Study Data." This webinar will review the guidance and discuss the implications for Sponsors currently conducting studies and for those starting new studies soon. Register today!